Amicus Therapeutics
Cranbury, NJ
2
staff members
Company Profile
Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. Unlike other treatments which replace defective enzymes, Amicus uses small molecule pharmacological "chaperones" which bind to a patient's own defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease. Another candidate, Plicera, is in development to treat Gaucher disease, while a third candidate, AT2220 is targeting Pompe disease. The company is also researching treatments for neurodegenerative diseases including Alzheimer's and Parkinson's.
51 to 200
TypeCompany - Public (FOLD)
Revenue$1 to $5 million (USD) per year
IndustryBiotech & Pharmaceuticals
CompetitorsActelion Group
Founded2005
Company site
Share Profile
Staff Members
CEO
Worked since Tuesday, Nov 04 2025
-
ManagerWorked since - -
CEOWorked since -
People Also Viewed
-
London, England (UK)Company size: 51 to 200 -
Garden City, NYCompany size: 51 to 200 -
Atlanta, GACompany size: 51 to 200 -
Culver City, CACompany size: 51 to 200 -
Fremont, California, United StatesCompany size: 240,000 -
Grapevine, TXCompany size: 1 to 50
Claim business page
Only the CEO can claim this profile. If you are the CEO, first
claim your profile and then claim your business page.
